Improving treatment of pancreatic cancer

The Lancet Oncology

Volumn 9, Issue 1, 2008, Pages 7-8

  Philip, Philip A ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE;

ADVANCED CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; GENE MUTATION; HUMAN; LETTER; MONOTHERAPY; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; HUMANS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 37449018357     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70391-1     Document Type: Letter

References (10)

1. Welch S., and Moore M. Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?. J Clin Oncol 25 (2007) 2159-2161
2. Cascinu S., Berardi R., Labianca R., et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol 9 (2007) 39-44
3. Philip P., Benedetti J., Fenoglio-Preiser C., et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. Proc Am Soc Clin Oncol 25 (2007) (abstr 4509).
4. Moore M., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
5. Xiong H., Rosenberg A., LoBuglio A., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22 (2004) 2610-2616
6. Burtness B., Powell M., Berlin J., et al. Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r) : Eastern Cooperative Oncology. Proc Am Soc Clin Oncol 25 (2007) (abstr 4519).
7. Xiong H., and Abbruzzese J. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29 5 Suppl 14 (2002) 31-37
8. Khambata-Ford S., Garrett C., Meropol N., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25 (2007) 3230-3237
9. Amado RG, Wolf M, Freeman D, et al. Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy. 14th European Cancer Conference. Barcelona, Spain. Sept 23-27, 2007. Abstract 0007.
10. Moore M., da Cunha Santos G., Kamel-Reid S., et al. The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3. Proc Am Soc Clin Oncol 25 (2007) (abstr 4521).